AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 152 filers reported holding AMYLYX PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.20 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4 | -33.3% | 3,150 | -30.0% | 0.00% | -100.0% |
| Q2 2023 | $6 | -64.7% | 4,500 | +45.2% | 0.00% | -50.0% |
| Q1 2023 | $17 | -85.7% | 3,100 | -8.8% | 0.00% | -80.0% |
| Q4 2022 | $119 | -100.0% | 3,400 | -96.5% | 0.01% | -64.3% |
| Q3 2022 | $407,000 | +157.6% | 96,725 | +847.3% | 0.03% | +154.5% |
| Q2 2022 | $158,000 | – | 10,211 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 2,756,050 | $35,415,000 | 3.44% |
| Boxer Capital, LLC | 2,200,000 | $28,270,000 | 1.45% |
| Alpha Wave Global, LP | 617,220 | $7,931,000 | 0.72% |
| Ikarian Capital, LLC | 396,654 | $5,097,000 | 0.67% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 768,603 | $9,877,000 | 0.58% |
| Ikarian Capital, LLC | 250,000 | $3,213,000 | 0.42% |
| 683 Capital Management, LLC | 677,714 | $7,685,000 | 0.41% |
| Perceptive Advisors | 1,474,107 | $18,942,000 | 0.38% |
| VIKING GLOBAL INVESTORS LP | 7,170,536 | $92,141,000 | 0.37% |
| Rock Springs Capital Management LP | 998,307 | $12,828,000 | 0.32% |